Overview

A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness and safety of CNTO 1275 in patients with Multiple Sclerosis
Phase:
Phase 2
Details
Lead Sponsor:
Centocor, Inc.
Collaborator:
Centocor BV
Treatments:
Ustekinumab